Karyopharm Therapeutics Financials

Summary - Funding Rounds

Founding Date

2008

Total Funding

$248.7 m

Investors

Karyopharm Therapeutics is a subsidiary of Biogen

Revenue/Financials

Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

387 k229 k250 k

Revenue growth, %

(41%)9%

R&D expense

28.5 m60.1 m97.7 m86.9 m

General and administrative expense

5.9 m15.9 m21.6 m23.9 m

Operating expense total

34.3 m76.1 m119.3 m110.9 m

EBIT

(34 m)(75.8 m)(119.1 m)(110.7 m)

EBIT margin, %

(8773%)(33121%)(47630%)

Interest expense

1 k1 k

Interest income

3 k97 k897 k1.3 m

Pre tax profit

(109.4 m)

Income tax expense

(139 k)

Net Income

(33.9 m)(75.8 m)(118.2 m)(109.6 m)

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

R&D expense

11 m13.2 m16 m20.8 m27 m25.9 m21.8 m24.6 m19.9 m24.1 m23.1 m25.2 m

General and administrative expense

2.9 m3.3 m3.8 m5.4 m6.2 m4.8 m5.6 m6 m5.9 m6.3 m6.6 m5.8 m

Operating expense total

13.9 m16.5 m19.8 m26.2 m33.2 m30.7 m27.3 m30.5 m25.8 m30.3 m29.8 m31.1 m

EBIT

(13.7 m)(16.4 m)(19.7 m)(26.2 m)(33 m)(30.6 m)(27.3 m)(30.5 m)(25.7 m)(30.3 m)(29.8 m)(31.1 m)

Interest expense

18 k

Interest income

18 k17 k20 k141 k267 k239 k286 k329 k311 k400 k412 k454 k

Pre tax profit

(29.9 m)(29.4 m)(30.6 m)

Income tax expense

(23 k)(18 k)(13 k)

Net Income

(13.7 m)(16.4 m)(19.7 m)(26.1 m)(32.7 m)(30.4 m)(27.1 m)(30.2 m)(25.4 m)(29.9 m)(29.4 m)(30.6 m)

Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

156 m150.6 m58.4 m49.7 m

Inventories

2 m2 m2 m2.1 m

Current Assets

158 m207.8 m177.6 m131.6 m

PP&E

240 k2.8 m3.5 m2.8 m

Total Assets

158.2 m220.3 m215.4 m180.4 m

Accounts Payable

1.7 m6.3 m3.8 m4.8 m

Current Liabilities

3.3 m12.3 m15.1 m16.5 m

Total Liabilities

18.1 m

Additional Paid-in Capital

217.5 m345.2 m455.2 m528.6 m

Retained Earnings

(138.3 m)(256.5 m)(366.1 m)

Total Equity

154.9 m206.8 m198.4 m162.2 m

Financial Leverage

1 x1.1 x1.1 x1.1 x

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

144.9 m132.3 m227.1 m51.5 m24.2 m43.5 m42.2 m37.7 m43.9 m25.6 m55.4 m54.5 m

Current Assets

147.6 m135.3 m231.3 m249.3 m225.3 m198.3 m138.1 m124.2 m130.3 m112.2 m145.7 m121.7 m

PP&E

322 k604 k2.7 m3.3 m3.2 m3.7 m3.3 m3.2 m3 m2.7 m2.5 m2.3 m

Total Assets

149.3 m137.7 m235.2 m292 m263.3 m237 m192.1 m170.9 m183.6 m155.4 m185.8 m163.8 m

Accounts Payable

3.3 m3.5 m2.1 m7 m4.5 m4.6 m4.1 m4.1 m2.2 m4.2 m3.2 m1.9 m

Current Liabilities

5 m5.6 m6.2 m14.7 m14.1 m14.4 m13.2 m15.5 m15 m15.5 m17.5 m21.2 m

Total Liabilities

6 m7.4 m16.5 m16 m16.4 m15.1 m17.3 m16.7 m17.1 m19 m22.6 m

Additional Paid-in Capital

220.4 m224.4 m340.2 m439.9 m444.6 m448.1 m460.5 m467.2 m506.1 m534.8 m592.5 m597.6 m

Retained Earnings

(92.7 m)(112.4 m)(164.4 m)(197.1 m)(227.5 m)(283.6 m)(313.7 m)(339.2 m)(396.3 m)(425.7 m)(456.3 m)

Total Equity

144.1 m131.7 m227.8 m275.5 m247.3 m220.6 m177 m153.6 m166.9 m138.4 m166.7 m141.2 m

Financial Leverage

1 x1 x1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.2 x

Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(33.9 m)(75.8 m)(118.2 m)(109.6 m)

Depreciation and Amortization

144 k323 k634 k717 k

Inventories

(1.4 m)(45 k)(55 k)(120 k)

Accounts Payable

664 k4.5 m(2.4 m)945 k

Cash From Operating Activities

(30.3 m)(51.4 m)(94 m)(84.4 m)

Purchases of PP&E

(57 k)(2.8 m)(1.4 m)(70 k)

Cash From Investing Activities

(57 k)(67 m)(90.8 m)24.6 m

Cash From Financing Activities

185.9 m113.1 m92.7 m51.2 m

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(13.7 m)(16.4 m)(19.7 m)(26.1 m)(32.7 m)(30.4 m)(27.1 m)(30.2 m)(25.4 m)(29.9 m)

Accounts Payable

3.5 m2.1 m7 m4.5 m4.6 m4.1 m4.1 m2.2 m4.2 m
Report incorrect company information

Operating Metrics

FY, 2015

Patents Issued

10
Report incorrect company information